Remote Prescribing of Gene Therapies: Restrictions

Introduction

Remote prescribing of gene therapies means authorising a genetic or cellular treatment through telemedicine without the patient and prescribing clinician being physically present together. Gene therapies may involve viral vectors, genetically modified cells, or other methods that alter gene expression or cellular function. They can carry serious risks, including immune reactions, unintended genetic effects, and long-term complications.

Unlike routine medicines, gene therapies often require specialised diagnosis, eligibility assessment, controlled administration, and prolonged follow-up. Remote prescribing therefore raises questions about whether telemedicine is clinically appropriate, whether the prescriber is qualified, and whether the treatment can lawfully be supplied and administered outside an authorised facility.

In India, there is no single statute specifically titled “remote gene-therapy prescribing law.” Restrictions arise from the Drugs and Cosmetics Act and Rules, biomedical and clinical regulations, telemedicine standards, and the rules governing research and advanced biological products. A remote consultation does not, by itself, authorise an otherwise unapproved gene therapy or remove requirements for specialised administration and monitoring.

Principal Restrictions

1. Prescriber qualification and diagnostic basis

The Telemedicine Practice Guidelines require a registered medical practitioner (RMP) to have adequate and relevant information about the patient before prescribing. The doctor must reach a reasoned diagnosis and determine that the treatment is appropriate. Gene therapy commonly requires specialist assessment, genetic testing, and review of clinical eligibility; a brief remote consultation alone may not provide a sufficient basis.

National Medical Commission+1

2. Product approval and clinical-trial controls

The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019 require gene-therapy clinical trials to comply with the New Drugs and Clinical Trials Rules, 2019. Trials must be conducted in adequately equipped medical institutions with tertiary-care facilities, appropriate specialist investigators, consent safeguards, and long-term recordkeeping. An investigational therapy cannot lawfully be treated as an ordinary prescription medicine merely because a doctor issues an e-prescription.

2019+2

India also amended the Drugs Rules in July 2026 to bring gene therapeutic products, cell or stem-cell-derived products, and xenografts under the Centrally License Approving Authority framework. This reinforces regulatory control over such products, though it does not itself create a specific prohibition on every remote consultation.

Press Information Bureau

3. Administration and follow-up

Gene therapies may require controlled infusion or specialised administration, emergency preparedness, monitoring for adverse reactions, and extended follow-up. Telemedicine rules restrict prescribing injectable medicines in certain circumstances: the RMP must be confident in the facility and the technical expertise of the administering RMP or health worker. This is especially important for high-risk gene therapies.

National Medical Commission+1

Relevant Case Laws

1. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

The Supreme Court held that valid medical consent must be voluntary and based on adequate information about the nature, purpose, benefits, alternatives, and substantial risks of treatment. Applied to gene therapy, consent should address the irreversible or long-term implications where relevant, foreseeable risks, available alternatives, and follow-up requirements. The judgment concerned surgery, not gene therapy, so its application is by analogy.

Indian Kanoon+1

2. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

The Court held that criminal medical negligence requires a high degree of negligence; an error of judgment or unsuccessful treatment does not automatically establish criminal liability. In remote gene-therapy prescribing, a doctor’s failure to assess eligibility or arrange necessary monitoring could raise liability questions, but criminal responsibility requires proof of the applicable legal standard and causation.

Indian Kanoon

3. K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1

The Supreme Court recognised privacy as a fundamental right. Genetic information can reveal highly personal information about an individual and their family. Collection, use, and sharing of genetic data for remote prescribing must therefore respect applicable privacy and data-protection obligations. This is a constitutional privacy precedent, not a gene-therapy prescribing case.

Sci API

Conclusion

Remote prescribing of gene therapies is restricted not simply because it is remote, but because gene therapies involve specialised products, complex eligibility decisions, serious risks, and potentially long-term consequences. The prescriber must be appropriately qualified, establish a sound clinical basis, ensure that the product is lawfully approved or used within an authorised trial, obtain valid consent, and arrange safe administration and monitoring.

No specific Indian reported judgment directly establishes a separate legal rule for remote prescribing of gene therapies. The cases discussed provide general principles on consent, negligence, and privacy; the principal restrictions arise from the statutory and regulatory framework.

2019+2